◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › ALNY

Alnylam Pharmaceuticals Inc (ALNY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-21

Alnylam Pharmaceuticals Inc (ALNY) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 2,500 employees. Its market capitalization is roughly $36 billion. In the fiscal year ended 2025-12-31, ALNY reported $3.7B in revenue and $314M in net income.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Interactive charts & full statements → Open the ALNY valuation workbench →

ALNY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.3B	$3.7B	$2.2B	$1.8B	$1.0B	$844M	$493M	$220M	$75M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
Gross Profit	$3.5B	$3.0B	$1.9B	$1.5B	$869M	$704M	$415M	$195M	$73M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
Gross Margin %	80.9%	81.8%	85.6%	83.0%	83.7%	83.4%	84.2%	88.6%	97.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$752M	$502M	($177M)	($282M)	($785M)	($709M)	($828M)	($939M)	($815M)	($500M)	($425M)	($296M)	($405M)	($93M)	($129M)	($55M)	($44M)	($48M)	($28M)	($93M)	($40M)
Operating Margin %	17.5%	13.5%	-7.9%	-15.4%	-75.7%	-83.9%	-168.1%	-427.5%	-1087.6%	-556.2%	-900.3%	-720.3%	-801.0%	-197.0%	-194.0%	-66.2%	-44.0%	-47.9%	-28.9%	-183.1%	-146.7%
Net Income	$577M	$314M	($278M)	($440M)	($1.1B)	($853M)	($858M)	($886M)	($761M)	($491M)	($410M)	($290M)	($360M)	($89M)	($106M)	($58M)	($44M)	($48M)	($26M)	($85M)	($35M)
Net Margin %	13.5%	8.5%	-12.4%	-24.1%	-109.0%	-101.0%	-174.2%	-403.2%	-1016.6%	-546.0%	-869.6%	-705.8%	-712.8%	-189.2%	-158.9%	-69.7%	-43.5%	-47.3%	-27.3%	-167.9%	-128.5%
EBITDA	$924M	$631M	($179M)	($258M)	($927M)	($662M)	($736M)	($885M)	($754M)	($487M)	($409M)	($277M)	($172M)	($83M)	($52M)	($50M)	($38M)	($41M)	($19M)	($75M)	($36M)
Earnings Per Share (EPS)	$4.18	$2.33	$-2.18	$-3.52	$-9.30	$-7.20	$-7.46	$-8.11	$-7.57	$-5.42	$-4.79	$-3.45	$-4.85	$-1.45	$-2.11	$-1.36	$-1.04	$-1.14	$-0.64	$-2.21	$-1.09
Shares Outstanding (M)	138M	135M	128M	125M	122M	118M	115M	109M	101M	91M	86M	84M	74M	62M	50M	42M	42M	42M	41M	39M	32M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.2B	$1.1B	$1.2B	$774M	$594M	$593M	$501M	$660M
Gross Profit	$956M	$829M	$1.1B	$631M	$523M	$490M	$415M	$591M
Gross Margin %	81.9%	75.6%	84.2%	81.5%	88.0%	82.7%	82.8%	89.6%
Operating Income (EBIT)	$269M	$132M	$368M	($16M)	$18M	($105M)	($77M)	$49M
Operating Margin %	23.0%	12.0%	29.5%	-2.1%	3.0%	-17.7%	-15.3%	7.4%
Net Income	$206M	$186M	$251M	($66M)	($57M)	($84M)	($112M)	($17M)
Net Margin %	17.6%	17.0%	20.1%	-8.6%	-9.7%	-14.1%	-22.3%	-2.6%
EBITDA	$304M	$304M	$297M	$19M	$11M	($141M)	($60M)	$37M
Earnings Per Share (EPS)	$1.49	$1.37	$1.83	$-0.51	$-0.44	$-0.65	$-0.87	$-0.13
Shares Outstanding (M)	138M	136M	137M	130M	130M	129M	129M	127M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$713M	$524M	($8M)	$104M	($541M)	($642M)	($615M)	($278M)	($563M)	($383M)	($308M)	($189M)	($166M)	($69M)	($116M)	($87M)	($84M)	($72M)	$65M	$197M	($25M)
Capital Expenditures (CapEx)	$72M	$59M	$34M	$62M	$72M	$76M	$70M	$140M	$127M	$104M	$65M	$13M	$9M	$4M	$8M	$1M	$5M	$5M	$11M	$8M	$5M
Free Cash Flow (FCF)	$641M	$465M	($43M)	$42M	($613M)	($718M)	($685M)	($419M)	($690M)	($487M)	($372M)	($202M)	($175M)	($73M)	($124M)	($88M)	($89M)	($77M)	$55M	$189M	($30M)
FCF Margin %	15.0%	12.5%	-1.9%	2.3%	-59.1%	-85.0%	-139.1%	-190.5%	-920.5%	-541.6%	-789.4%	-491.7%	-345.3%	-154.1%	-185.8%	-106.8%	-89.0%	-76.7%	56.9%	370.8%	-110.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$71M	$164M	$325M	$154M	($118M)	($95M)	$44M	$124M
Capital Expenditures (CapEx)	$22M	$23M	$12M	$14M	$9M	$9M	$4M	$8M
Free Cash Flow (FCF)	$49M	$140M	$313M	$139M	($127M)	($104M)	$40M	$116M
FCF Margin %	4.2%	12.8%	25.1%	18.0%	-21.4%	-17.5%	7.9%	17.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALNY Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$5.1B	$5.0B	$4.2B	$3.8B	$3.5B	$3.6B	$3.4B	$2.4B	$1.6B	$2.0B	$1.3B	$1.4B	$1.1B	$421M	$288M	$282M	$393M	$481M	$555M	$494M	$240M
Cash & Cash Equivalents	$1.7B	$1.7B	$966M	$813M	$866M	$820M	$497M	$547M	$420M	$645M	$194M	$181M	$75M	$53M	$51M	$70M	$75M	$137M	$192M	$105M	$128M
Total Liabilities	$4.1B	$4.2B	$4.2B	$4.1B	$3.7B	$3.1B	$2.4B	$956M	$273M	$228M	$343M	$122M	$143M	$150M	$153M	$164M	$235M	$303M	$353M	$295M	$39M
Total Debt (Short + Long-Term)	$1.1B	$1.1B	$1.2B	$1.1B	$1.1B	$716M	$228M	$28M	$93M	$41M	$161M	$7M	$5M	$3M	$4M	$63M	$11M	$4M	$6M	$5M	$9M
Total Shareholders' Equity	$1.1B	$789M	$67M	($221M)	($158M)	$588M	$1.0B	$1.4B	$1.3B	$1.8B	$920M	$1.3B	$936M	$270M	$134M	$118M	$158M	$178M	$202M	$199M	$201M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALNY viewer.

Other Companies in BIOTECHNOLOGY

RVMD · Revolution Medicines Inc — $40 billion
RPRX · Royalty Pharma Plc — $34 billion

← ALNT All stocks ALOT →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.